Reducing downstream costs with diagnostic and prognostic testing
At Mayo Clinic, we know the importance of laboratory testing in a patient’s episode of care. Our unique combination of specialized laboratories and cardiology patient care clinics allows us to reduce downstream costs with care-driven testing approaches that produce definitive diagnoses. Our testing can also identify at-risk patients who require earlier intervention or increased surveillance through the most advanced techniques and technologies developed and validated in clinical practice.
OUR DIFFERENCE
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent news about the use of artificial intelligence (AI) tools in healthcare.
This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for September include the following sub-specialties: Cardiovascular Pathology, Cytopathology, Cytogenetics, Hematopathology, and Laboratory Genetics and Genomics.
In this month's "Hot Topic," Linnea Baudhuin, Ph.D., discusses Mayo Clinic Laboratories’ up-to-date gene panel tests for cardiomyopathies and arrhythmias, connective tissue and vascular fragility disorders, dyslipidemias, and congenital heart disease.
From friendly neighbor, to a hero. Darin Kittleson was in the middle of his ordinary day snow plowing his driveway when he decided to plow his neighbor’s driveway, as well. That was when he heard the cry for help. Darin rushed inside as 911 was being called, he immediately started performing CPR, which in the end saved his neighbor’s life.
Jeffrey (Jeff) Meeusen, Ph.D., gives an overview of the new nuclear magnetic resonance (NMR) lipoprotein profile available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
After a long wait, the U.S. Food and Drug Administration has finally approved the Elecsys Troponin T Gen 5 STAT blood test. Recently, the Beckman hscTnI assay was also approved. These high-sensitivity troponin assays will benefit emergency departments across the country because the results will allow for earlier and faster recognition of acute myocardial infarction, which interrupts the blood supply to an area of the heart.
High-sensitivity troponin T is a new assay recently approved by the U.S. Food and Drug Administration. This assay is most often used to evaluate patients with possible acute ischemic heart disease, but it also has a variety of uses in the more chronic setting.